New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
R&D Expenses
1.54 0.96 3.09 2.32 3.17 6.88 11.49 5.80 7.27 7.81
SG&A Expenses
0.38 0.84 1.44 1.61 3.26 4.69 8.76 5.66 4.78 6.18
Operating Income
(1.92) (1.80) (4.52) (3.94) (15.14) (12.13) (20.26) (11.46) (12.05) (13.99)
Non-operating Income/Expense
0.00 (0.05) (0.14) (0.03) (0.28) 0.18 (7.17) 0.34 0.20 0.42
Non-operating Interest Expenses
0.00 0.06 0.16 0.04 0.28 — — — — —
EBT
(1.92) (1.86) (4.67) (3.96) (15.41) (11.96) (27.42) (11.12) (11.85) (13.56)
Income Tax Provision
— — (0.90) (0.60) (1.00) (0.53) — — — —
Income after Tax
(1.92) (1.86) (3.76) (3.36) (14.41) (11.43) (27.42) (11.12) (11.85) (13.56)
Dividends (Preferred)
— — — 0.51 4.63 — — — — —
Net Income Common
(1.92) (1.86) (3.76) (3.86) (14.41) (11.43) (27.42) (11.12) (11.85) (13.56)
EPS (Basic)
(228.93) (210.08) (350.14) (350.00) (960.92) (375.00) (850.00) (212.00) (96.75) (10.36)
EPS (Diluted)
(228.93) (210.08) (350.14) (350.00) (960.92) (375.00) (850.00) (212.00) (96.75) (10.36)
Shares (Basic, Weighted)
0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.12 1.31
Shares (Diluted, Weighted)
0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.12 1.31
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% — — —
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBT margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Profit Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA
(1.92) (1.78) (4.52) (3.13) (14.33) (11.34) (19.35) (11.46) (12.05) (13.99)
EBIT
(1.92) (1.80) (4.52) (3.94) (15.14) (12.13) (20.26) (11.46) (12.05) (13.99)
Income from Continuous Operations
(1.92) (1.86) (3.76) (3.36) (14.41) (11.43) (27.42) (11.12) (11.85) (13.56)
Consolidated Net Income/Loss
(1.92) (1.86) (3.76) (3.36) (14.41) (11.43) (27.42) (11.12) (11.85) (13.56)
EPS (Basic, from Continuous Ops)
(228.93) (199.40) (353.06) (303.83) (960.92) (372.99) (851.18) (211.99) (96.81) (10.36)
EPS (Basic, Consolidated)
(228.93) (199.40) (353.06) (303.83) (960.92) (372.99) (851.18) (211.99) (96.81) (10.36)
EPS (Diluted, from Cont. Ops)
(228.93) (199.40) (353.06) (303.83) (960.92) (372.99) (851.18) (211.99) (96.81) (10.36)
Shares (Diluted, Average)
0.00 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.12 1.31
EPS (Diluted, Consolidated)
(228.93) (199.40) (353.06) (303.83) (960.92) (372.99) (851.18) (211.99) (96.81) (10.36)
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 18 Nov 2026